ATX-1209
Opioid Use Disorder, Chronic Pain (adjunct), Neonatal Opioid Withdrawal Syndrome
Key Facts
About aether THERAPEUTICS
Aether Therapeutics is a private, clinical-stage biotech focused on transforming the treatment of opioid addiction and chronic pain through a novel pharmacological approach. The company's core asset, ATX-1209, is an addiction modulator designed to reverse the upregulated basal mu-opioid receptor signaling that drives dependence. Recent key leadership appointments, including a Chief Medical Officer with deep regulatory experience in addiction medicine and a renowned neuroscientist to its Board, signal a strategic push towards clinical development and underscore the program's scientific credibility. Aether is positioned to address a critical and underserved public health crisis with a potentially differentiated mechanism of action.
View full company profile